Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 11:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2353–2376 of 50,397 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer Clear all

Conditions: Acute Myelogenous Leukemia
Interventions: aldesleukin, natural killer cells, cyclophosphamide, fludarabine phosphate, allogeneic hematopoietic stem cell transplantation, total body irradiation, Thymoglobulin, Cyclosporin A; Biological · Drug · Procedure + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Brain and Central Nervous System Tumors, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: filgrastim, sargramostim, therapeutic autologous lymphocytes, O6-benzylguanine, carmustine, temozolomide, in vitro-treated peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Breast Cancer, Autoimmune Disease, Prostate Cancer, Ovarian Cancer, Endometrial Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 10,805 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Azer-cel, Fludarabine, Cyclophosphamide, IL-2, Ibrutinib, Acalabrutinib, Zanubrutinib, or Pirtobrutinib; Biological · Drug
Lead sponsor: Imugene Limited; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 10
States / cities: Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 6 more

Conditions: Choriocarcinoma
Interventions: TRC105, Bevacizumab; Biological
Lead sponsor: Tracon Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Colorectal Cancer, Cancer Screening
Interventions: Small Media; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 50 Years to 75 Years
Enrollment: 1,707 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Ductal Carcinoma in Situ
Interventions: Cryoablation; Procedure
Lead sponsor: Glendale Adventist Medical Center d/b/a Adventist Health Glendale; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Glendale, California

Conditions: Neoplasms, Prostate
Interventions: dutasteride, placebo, bicalutamide; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 90 Years · Male only
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 47
States / cities: Homewood, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 43 more

Conditions: Colorectal Cancer, Colon Cancer
Interventions: Aspirin, Vitamin D, Diet, Physical Activity, Behavioral Support Counseling Sessions; Drug · Dietary Supplement · Other + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage
Interventions: revumenib, cobicistat; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 30 Days and older
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 22
States / cities: Duarte, California • Los Angeles, California • Palo Alto, California + 17 more

Conditions: Metastatic Castration-Resistant Prostate Carcinoma
Interventions: Non-Interventional Study; Other
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Cancer
Interventions: Not listed
Lead sponsor: Tempus AI; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 31
States / cities: Birmingham, Alabama • Whittier, California • Norwich, Connecticut + 26 more

Conditions: Recurrent Melanoma, Stage IV Melanoma
Interventions: Raf kinase inhibitor LGX818, binimetinib, laboratory biomarker analysis; Drug · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer, Lung Cancer, Mediastinal Lymphomas
Interventions: Radiation Therapy; Radiation
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Leukemia
Interventions: choline magnesium trisalicylate, Dexamethasone; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Localized Prostate Cancer
Interventions: TOOKAD®; Drug
Lead sponsor: Steba Biotech S.A.; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: celecoxib 400 mg bid; Drug
Lead sponsor: University of Kansas; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 7
States / cities: Birmingham, Alabama • Palm Springs, California • Maywood, Illinois + 4 more

Conditions: Squamous Cell Carcinoma
Interventions: Diffusion-weighted imaging magnetic resonance imaging, FDG PET/CT; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions: bortezomib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2001
U.S. locations: 1
States / cities: New York, New York

Conditions: Head and Neck Cancer, Head and Neck Cancers
Interventions: Dichloroacetate, EF5; Drug · Device
Lead sponsor: Daniel T. Chang; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: Li-Fraumeni Syndrome
Interventions: Whole Body MRI; Device
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: Not listed
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2027
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania

Conditions: Colorectal Cancer Screening
Interventions: 3 sample g-SENSA, 2 sample InSure, 1 sample OC-Micron; Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 50 Years to 74 Years
Enrollment: 2,260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Metastatic Melanoma
Interventions: ipilimumab, nivolumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 13
States / cities: Hartford, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 7 more

Conditions: Generalized Myasthenia Gravis
Interventions: Rozanolixizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 30
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 23 more

Search by objective public record fields.

Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant

Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Continuation of Follow-up of DES-Exposed Cohorts

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma

Small Media Interventions to Increase Colorectal Cancer Screening Among Chinese Americans

Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ

Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy

DAILY: Vitamin D, Aspirin, ExercIse, Low Saturated Fat Foods StudY in Colorectal Cancer Patients With Minimal Residual Disease

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy

TEMPUS ARIES: A Biobank Registry Platform Study in Oncology

Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations

Cardiotoxicity of Radiation Therapy (CTRT)

Gene Expression During Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Choline Magnesium Trisalicylate

Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer

A Study of Women With an Early Diagnosis of Breast Cancer, Taking Celecoxib Between the Biopsy and Lumpectomy/Mastectomy

Optimized Diffusion-Weighted Imaging for the Evaluation of Post-Treatment Squamous Cell Carcinoma in the Neck: Comparative Study With FDG PET/CT

PS-341 in Treating Patients With Hematologic Cancer

Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers

Screening With Whole Body MRI For Detection Of Primary Tumors In Children And Adults With Li-Fraumeni Syndrome (LFS) And Other Cancer Predisposition Syndromes

Systems of Support (SOS) to Increase Colon Cancer Screening and Follow-up Supplement

A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy

A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis